Siemens Healthineers Faces a Pivotal Earnings Test Amid Strategic Shifts

Siemens Healthineers faces Q2 pressure from China, tariffs, and weak diagnostics. CEO bets on AI and radiopharmaceuticals for a strategic turnaround.

Investors in Siemens Healthineers are bracing for a critical update on May 7, when the company reports its second-quarter figures. The report arrives at a tense moment, with the stock trading at €38.68, nearly 13% down year-to-date and roughly 14% below its level from a year ago. The upcoming numbers must address significant operational pressures while justifying a major strategic bet on artificial intelligence.

The immediate financial headwinds are substantial. U.S. tariffs are expected to weigh on the company’s adjusted operating profit this year by approximately €400 million, with negative currency effects costing an additional three-digit million-euro sum. These pressures have forced management to lower its guidance; the forecast for adjusted earnings per share now stands at a maximum of €2.40, a starkly muted outlook compared to last year’s €2.39.

A primary source of weakness is the diagnostics division, which is struggling globally. The situation is particularly acute in China, where a state anti-corruption campaign and centralized procurement rules are hampering sales. Jerry Wang, the Country President in China, recently acknowledged a changing market environment with slowing growth, as local competitors like United Imaging Healthcare and Mindray gain ground. Analysts see this not as a temporary blip but as a structural shift in the Chinese medtech market that will continue to unfold.

Against this challenging backdrop, CEO Bernd Montag is launching a strategic offensive in high-margin digital health. The company has recruited Martin Stumpe, a veteran from Danaher, Google, and NASA, to become its new Chief Technology Officer starting in June 2026. He will replace Peter Schardt, who held the role for seven years. Stumpe’s mandate is to massively expand the company’s capabilities in artificial intelligence, with a focus on "Patient Twinning"—technology that creates digital replicas of patients to enable more precise diagnoses and efficient hospital workflows. Stumpe is set to make his first major appearance for the company at the DMEA trade fair in Berlin on April 21.

Parallel to its AI push, Siemens Healthineers is advancing its radiopharmaceuticals business. A new agreement with Radiopharm Theranostics secures the production of the imaging agent RAD101, which aids in diagnosing hard-to-detect brain metastases. The U.S. FDA has granted the agent Fast-Track status, significantly accelerating its regulatory pathway, with early study data showing high concordance with conventional MRI scans.

The market remains skeptical of the near-term outlook. Morgan Stanley recently cut its price target on the stock from €44 to €41, maintaining an "Equal Weight" rating due to weaker margin prospects and subdued dynamics in the equipment business. The current share price sits about 7% above its late-March yearly low of €38.25 but remains well below the 200-day moving average of €44.15. A clear breakout above the 50-day average of €39.35 is seen as a near-term technical hurdle.

The first quarter saw revenue of €5.4 billion and adjusted EPS of €0.49. For the full year, the company targets revenue growth of five to six percent. The May 7 report will be scrutinized for solid growth in the imaging division, continued diagnostics weakness, and, most importantly, management’s plan to navigate the €400 million in operational headwinds. The results will likely determine whether the stock can begin a sustained recovery or if the yearly low will come back into view.